The antibody staining of each target was initially optimised using two different tissue controls (a normal tonsil and a BC) and further validated on an independent series of HER2+ BC stained by regular IHC to ensure consistent results among methods (Supplementary Figs. 2 and 3). Here, ERBB2 is linked to breast cancer.